Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532712 | 0.84 | PDE4A (0.41) | BACE1CYP2D6BACE2 | |
| SCHEMBL3367319 | 0.83 | ADORA1 (0.41) | BACE1CYP2D6CTSDADORA1BACE2 | |
| SCHEMBL5536001 | 0.83 | BACE1 (0.38) | BACE1CYP2D6SIGMAR1CTSDADORA1 | |
| SCHEMBL1635144 | 0.79 | BACE1 (0.38) | BACE1CTSDBACE2 | |
| SCHEMBL27696441 | 0.73 | ADORA1 (0.43) | BACE1CYP2D6SIGMAR1CTSDADORA1 | |
| SCHEMBL5350872 | 0.72 | BACE1 (0.36) | BACE1CYP2D6SIGMAR1CTSDBACE2 | |
| SCHEMBL3367170 | 0.71 | BACE1 (0.59) | BACE1CTSDBACE2 | |
| SCHEMBL3362226 | 0.69 | BACE1 (0.63) | BACE1SIGMAR1BACE2 | |
| SCHEMBL5535995 | 0.67 | PDE4A (0.44) | BACE1CYP2D6BACE2 | |
| SCHEMBL3367313 | 0.67 | PDE4A (0.45) | BACE1ADORA1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | BACE1 2/4885CYP2D6 4141/4885SIGMAR1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.